The deal announced Monday, July 11 for the French pharmaceutical company, Sanofi, to sell off its its dermatology unit, Dermik Laboratories, Inc., to Canada-based Valeant Pharmaceuticals International Inc. (VRX) for $425 million in cash. The acquisition involves Dermik’s assets, comprising of an aesthetic and therapeutic dermatology business in the U.S. and Canada, along with other aesthetic dermatology businesses in other parts of the world. The transaction will also include and a manufacturing facility in Laval near Montreal. Dermik was reported to have revenues of $206 million.
If you are interested in further details about this transaction, please check out our deal profile below.